Avoro Capital Advisors LLC
Q4 2023 13F-HR Holdings
Net value change ($000)
+828,537
(12.9%)
New positions
6
Sold out positions
9
Turnover %
26.9%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q3 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| XBI | 396,844 | NEW |
| Cerevel Therapeutics Holdings, Inc. | 299,496 | 1435.7% |
| APLS | 242,444 | 57.4% |
| MDGL | 209,959 | 92.5% |
| Intra-Cellular Therapies, Inc. | 161,543 | NEW |
| ASND | 129,353 | 37.6% |
| CymaBay Therapeutics, Inc. | 108,871 | 70.9% |
| XENE | 93,623 | 55.9% |
| BMRN | 73,958 | 21.7% |
| FOLD | 55,622 | 16.7% |
Top Reduces (Value $000, Stocks/ETFs)
| Horizon Therapeutics Public Ltd Co | -809,830 | -100.0% |
| Seagen Inc. | -373,300 | -100.0% |
| SRPT | -68,976 | -14.1% |
| RARE | -36,738 | -68.7% |
| AKRO | -28,100 | -100.0% |
| TNGX | -25,022 | -100.0% |
| NUVL | -24,184 | -64.7% |
| ARGX | -21,964 | -4.5% |
| PMVP | -18,420 | -100.0% |
| UTHR | -15,653 | -2.4% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|